EDX-MEDICAL
26.6.2024 10:22:30 CEST | Business Wire | Press release
EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces today it has signed an exclusive distribution agreement with Curesponse Ltd, to market the cResponse™ cancer assay in the UK, Sweden, Finland, Norway and Denmark.
cResponse™ is a groundbreaking platform that biologically assesses how an individual patient’s living tumour tissue responds to selected medicines, identifying the most effective treatment options. It is the only clinical-grade technology providing biological response data for chemotherapy, targeted biologics, and immunotherapy drugs. This platform helps clinicians rapidly pinpoint optimal treatments, potentially saving lives, reducing treatment costs, and accelerating the discovery and development cycles for pharmaceutical companies seeking new cancer drugs.
The cResponse™ platform generates a report ranking selected cancer drugs based on their predicted effect on an individual patient’s tumour, demonstrating over 90% accuracy in clinical trials. The test can be augmented with rapid genomic sequencing to identify additional drug candidates for functional analysis. The entire process is powered by proprietary technologies and advanced AI algorithms. The platform technology has been refined and calibrated using thousands of cancer tissues, demonstrating its clinical utility and effectiveness through hundreds of cases in Israel and the UK. The cResponse™ test is performed at a United Kingdom Accreditation Service (UKAS) accredited lab in London and has also earned a CE mark for Europe, underscoring its regulatory approval and readiness for clinical use.
EDX Medical will initiate commercial activities to support the clinical use of the cResponse™ assay in the UK and Nordics with immediate effect and will explore broadening the agreement with Curesponse in due course.
Professor Sir Chris Evans, OBE, founder of EDX Medical plc, commented: “We are delighted to be increasing accessibility to this genuinely innovative and pioneering test which potentially offers tremendous benefit to those treating cancer and their patients. This product is an excellent addition to our rapidly growing portfolio of class-leading diagnostic solutions.”
Dr Mike Hudson, CEO, EDX Medical plc, said: “We are very pleased to have been selected by Curesponse as their partner, and to be able to make their breakthrough assay available for our clients in the UK and Nordics. We consider cResponse™ to be an outstanding innovation in the fast-moving clinical cancer diagnostic landscape.”
Guy Neev, CEO of Curesponse Ltd, commented: “We are thrilled to partner with EDX Medical Group to bring our cResponse™ platform to patients and clinicians in the UK and Nordic countries. Our mission at Curesponse is to make this technology available to cancer patients to optimize treatment outcomes and save lives. This collaboration is a significant step toward achieving that goal. We look forward to working closely with the EDX Medical team to ensure the successful adoption and implementation of this groundbreaking decision support tool.”
About EDX Medical Group plc
The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX). www.edxmedical.com
About Curesponse Ltd. Curesponse is a pioneering leader in precision oncology. www.curesponse.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626860842/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hitachi Joins Anthropic’s Critical Infrastructure Defense Program9.10.2026 02:32:00 CEST | Press release
Hitachi, Ltd. (TSE:6501, "Hitachi"), today announced that it has joined Anthropic, PBC’s (“Anthropic”) “Critical Infrastructure Defense Program,” launched on October 8, 2026, as a founding partner. The program is aimed at strengthening cyber defense for critical infrastructure, including control systems supporting power, water, manufacturing, and transportation services. Infrastructure systems that underpin society and the economy cannot tolerate prolonged downtime, making it difficult to implement certain security measures, such as system shutdowns for patch deployment. At the same time, advances in AI are significantly shortening the time between vulnerability disclosure and exploitation, creating an urgent need to redesign systems based on the assumption that cyberattacks will occur. The program seeks to strengthen cybersecurity through rapid vulnerability detection and remediation by integrating Anthropic’s advanced AI models, Claude, into the products and services of trusted syste
Lapmaster Wolters and Precision Surfacing Solutions Secures Strategic Minority Investment from The Cynosure Group and Fernweh Group to Accelerate Growth8.10.2026 22:49:00 CEST | Press release
Investment strengthens the balance sheet and brings long-term strategic partners to support continued growth and expansion across semiconductors, advanced materials, advanced packaging, and precision optics end markets. Lapmaster Wolters and Precision Surfacing Solutions (“Lapmaster Wolters”), a leading global supplier of high-precision machine systems and consumables to the semiconductor, advanced materials, precision optics, and advanced packaging industries, today announced the completion of a minority equity investment by affiliates of The Cynosure Group (“Cynosure”) and Fernweh Group (“Fernweh”). The investment strengthens the balance sheet and adds long-term, engaged partners to support the company’s next phase of growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008141876/en/ Positioned for growth Demand for ultra-high-precision surface finishing continues to grow as customers in semiconductors, advanced mater
Dubai Launches Global Create AI Agents Championship with Prize Pool Exceeding AED 2.5 Million8.10.2026 19:05:00 CEST | Press release
Dubai has launched the Create AI Agents Championship, a global competition inviting innovators to develop practical and scalable AI-agent solutions that address real-world challenges, with a total prize pool exceeding AED 2.5 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008883373/en/ Dubai has launched the Create AI Agents Championship as part of its efforts to accelerate the adoption and development of Agentic AI (Photo: AETOSWire) The launch of the championship was announced by H.H. Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister and Minister of Defence of the UAE, and Chairman of The Executive Council of Dubai, who encouraged innovators from around the world to participate. Led by Dubai Chamber of Digital Economy, the championship aims to accelerate the adoption of Agentic AI and support the development of innovative AI-agent solutions with strong potential for
Seiden Law LLP issues statement: Prosecuted by Press Conference: Declared Guilty Without a Charge, Yim Leak Family Asks UN Human Rights Experts to Hold Thailand to Its Own Treaty Commitments8.10.2026 18:26:00 CEST | Press release
Urgent appeal to UN Special Rapporteurs cites the presumption of innocence, due process and protection of a child. The key facts are the Thai government's own words and files. Seiden Law LLP, chief global counsel to Cambodian businessman Yim Leak, announced today that Jared Genser, international counsel to Mr. Yim and his wife, has asked two UN Special Rapporteurs to send an urgent appeal to the Thai government. The request is made on behalf of the couple and their seven-year-old son. It says Thailand violated its international human rights commitments by announcing the family’s guilt before any court had tried them, and by freezing their assets, including their minor son’s savings, without a hearing. Six Official Statements in Nine Months. No Charge Filed in Any Court. Between December 2025 and September 2026, Thai officials described Mr. Yim as the center of a criminal network on six occasions: at two press conferences chaired by the head of the Thai government, in the House of Repre
Sam Altman-Backed Meanwhile Raises $37.5M as Families Across Asia, Europe and the Middle East Turn to Bitcoin Life Insurance8.10.2026 18:12:00 CEST | Press release
Existing investors, led by Bain Capital Crypto, back the first licensed Bitcoin life insurer after its single-premium policy for international clients drives a record year Meanwhile, the first life insurer licensed to operate entirely in Bitcoin, today announced $37.5 million in new funding from its existing investors. Bain Capital Crypto led the round, alongside Haun Ventures, Framework Ventures, Pantera Capital, Apollo, Northwestern Mutual Future Ventures, and Morgan Creek Digital. Meanwhile, whose backers also include Sam Altman, has now raised more than $180 million. The round follows a surge in international demand for Meanwhile’s Bitcoin life insurance policies, particularly in Asia, Europe and the Middle East amid broader macro instability. In early 2026, Meanwhile launched BTC Life 1-Pay, a single-premium whole life policy built for high-net-worth clients outside the United States. It is the company's second product line after BTC 10-Pay, which is purposely designed for US taxp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom